whatshot

LYEL   $20.77  3.54% Market Closed

Lyell Immunopharma, Inc.
show_chart Advanced Chart of LYEL
Last Events:

2023-08-09 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: main and signal line crossing.

2023-08-06 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Trend Power changed from medium strength to strong.

2023-08-05 Trend pattern changed from сужающийся канал to нисходящий треугольник.

2023-08-05 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-04 Trend pattern changed from расходящийся клин с наклоном вверх to сужающийся канал.

2023-08-04 Signal in Stochastic changed from bullish reversal to bearish recovery. The stochastic indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: main and signal line crossing.

Current temperature: 11.40
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 39.33
Mean unverified/preliminary 39.33 / 39.33
Target Price Low / High 34.00 / 45.00
Median / STD DEV 39.00 / 5.51
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy ActivelyBuy
rsi ActivelyBuy ActivelyBuy None
macd None None None
stoch ActivelyBuy None None
ma20 None ActivelyBuy None
ma50 ActivelyBuy None None
ma100 Buy ActivelyBuy ActivelyBuy
Candlestick PatternMarch 18, 2026 Long Legged - consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
ISIN US55083R2031
ceo Dr. Lynn Seely M.D., Ph.D.
Website https://lyell.com
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.